Initial trabeculectomy with 5-fluorouracil with or without subconjunctival bevacizumab in the management of pseudoexfoliation glaucoma
Session Details
Session Title: Presented Poster Session: Glaucoma
Venue: Poster Village: Pod 2
First Author: : U.Elgin TURKEY
Co Author(s): : E. Sen S. Colak P. Yilmazbas
Abstract Details
Purpose:
To investigate the outcomes of initial trabeculectomy with 5-fluorouracil (5-FU) with or without subconjunctival bevacizumab in the surgical management of pseudoexfoliation glaucoma (PXG).
Setting:
Ulucanlar Eye Research Hospital, Ankara, Turkey
Methods:
This retrospective study consisted of 49 cases with PXG who underwent initial trabeculectomy with 5-FU. The cases were divided into two age and sex-matched groups. In 23 cases subconjunctival bevacizumab was injected (1.25 mg/0.05 mL) at the end of the surgery and in 26 of them the surgery was performed without bevacizumab. The patients were evaluated for the postoperative differences of intraocular pressure (IOP) and the mean number of antiglaucomatous medications within the 6 months postoperatively. Independent t, Kolmogorov-Smirnov and chi square tests were used for statistical analysis.
Results:
Preoperative IOP of bevacizumab group (13 male, 10 female, mean age 67.91±4.92) was 30.91±4.50 mmHg (2.4±0.7 drops). The IOP decreased to 10.22±2.63 mmHg (first week), 10.91±1.88 mmHg (first month), 12.35±2.50 mmHg (3rd month) and 12.65±2.35 mmHg (sixth month). Preoperative IOP of the other group (14 male, 12 female, mean age 67.92±4.32) was 31.27±5.60 mmHg (2.3±0.7 drops). The IOP decreased to 10.08±2.59 mmHg (first week), 11.00±1.87 mmHg (first month), 12.81±2.04 mmHg (3rd month) and 13.62±2.21 mmHg (sixth month). In both groups IOP reduced significantly postoperatively. There were no significant differences between the preoperative and the postoperative IOP values of the groups.
Conclusions:
Though bevacizumab has antifibrotic activity, trabeculectomy with 5-FU with or without bevacizumab provides similar reduction of IOP in cases with PXG in 6-months follow-up period.
Financial Disclosure:
NONE
